Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

British Journal of Clinical Pharmacology

Volumn 72, Issue 2, 2011, Pages 263-269

  Malhotra, Bimal ^a   Dickins, Maurice ^b   Alvey, Christine ^a   Jumadilova, Zhanna ^a   Li, Xiaoxi ^a   Duczynski, Gregory ^a   Gandelman, Kuan ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Drug drug interactions; Fesoterodine; Fluconazole; Overactive bladder; Pharmacokinetics

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; FESOTERODINE; FLUCONAZOLE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD SAMPLING; BLURRED VISION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; VOMITING;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; YOUNG ADULT;

EID: 79960174276     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04007.x     Document Type: Article

References (22)

1. ® (Fesoterodine Fumarate). Full Prescribing Information. New York: Pfizer Inc, 2010.
2. European Medicines Agency (EMEA). EPARs for authorized medicinal products for human use. European Public Assessment Report for Toviaz (Product Information). Updated August 2009. Available at (last accessed 20 October 2009).
3. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-96.
4. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004; 29: 715-20.
5. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 556-63.
6. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5- hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009; 16: 4481-9.
7. Malhotra B, Gandelman K, Sachse R, Wood N. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol 2009; 49: 477-82.
8. de Mey C, Mateva L, Krastev Z, Sachse R, Wood N, Malhotra B. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. J Clin Pharmacol 2011; 51: 397-405.
9. Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol 2009; 65: 551-60.
10. Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft Guidance. September 2006. Available at (last accessed 20 October 2009).
11. European Agency for the Evaluation of Medicinal Products, Committee for Propietary Medicinal Products. Note for guidance on the clinical investigation of drug interactions. June 2008. Report No.: CPMP/EWP/560.95.
12. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-6.
13. Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol 2005; 45: 1187-97.
14. Ahonen J, Olkkola KT, Neuvonen P. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 51: 415-9.
15. Kunze KL, Wienkers LC, Thummel KE, Trager WF, Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-21.
16. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
17. Nitti V, Dmochowski R, Sand P, Forst H-T, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol 2007; 178: 2488-94.
18. Pfizer Inc. Diflucan (Fluconazole). Full Prescribing Information. New York: Pfizer Inc, 1990.
19. Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47: 779-92.
20. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007; 63: 941-9.
21. Saari TI, Olkkola KT. Azole antimycotics and drug interactions in the perioperative period. Curr Opin Anaesthesiol 2010; 23: 441-8.
22. Malhotra B, Sachse R, Wood N. Influence of food on the pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2009; 47: 384-90.